Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Key facts
- Who runs it
- Ourotech, Inc.
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 12 people enrolled
- Started
- 12 Oct 2023
- Ended
- 25 Jul 2025
- Type of study
- Observational
- Treatments tested
- Resection
- Record updated
- 30 July 2025
- Why it stopped
- Lack of funding
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Other criteria
- Inclusion:
- Patient diagnosed with operable brain cancer, thought likely to be primary solid brain tumor on imaging (grade 2 - 3 meningioma; grade 1 - 4 tumors otherwise) or with histologically proven primary malignant solid brain tumor
- Able to give written informed consent prior to admission to this study
- Female or male aged ≥18 years
- Patient consents to the use of their surgical sample and 40mL of whole blood for research purposes
- Surgical sample and yields ≥0.4g for the study
- Patient consents to providing histopathology data (e.g., confirmation of histological subtype as oligodendroglioma) and other pseudonymised health information including imaging, treatment and outcome data; Exclusion:
- Inoperable or biopsy only
- Suspected lymphoma or myeloma, or grade 1 meningioma
- Preoperative haemoglobin levels below 120g/L
- Patients who have already received chemotherapy, targeted therapy, immunotherapy, or radiotherapy less than 30 days before date of surgery, unless as part of a clinical trial (requires per-patient sponsor approval)
- Recurrence of cancer originating from a site other than the brain
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex vivo. This study will recruit patients with primary brain tumors who are due to undergo surgery.
Read full original descriptionShow less
Oncologists will be blinded to treatment response on the Pear Bio tool (the assay will be run in parallel with the patient's treatment). The primary objective of this study is to establish the ex vivo model and confirm whether approved therapies exhibit their intended mechanism of action in the model. Secondary objectives include correlating test results to patient outcomes, where available.
The group in the trial
- Trial Cohort
Patients with a solid primary brain tumor due to undergo surgery as standard of care
Treatment: Resection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 July 2025